Arca
Skip to content
Tools
Tools

BCL2: Apoptosis regulator Bcl-2

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on BCL2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Other 1

Approved1

  • Venetoclax

Phase 32

  • Navitoclax
  • Obatoclax

Phase 21

  • APG-2575

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Ascentage Pharma Group Inc.125%
    • Gemin X125%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Apoptosis regulator Bcl-2 inhibitor.
    VenetoclaxApprovedAbbVieSmall moleculeInhibitor538
    NavitoclaxPhase 3AbbVieSmall moleculeInhibitor10
    ObatoclaxPhase 3Gemin XSmall moleculeInhibitor0
    APG-2575Phase 2Ascentage Pharma Group Inc.OtherInhibitor20

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
    Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALLVenetoclaxPhase 2Not yet recruitingRuijin HospitalNov 17, 2026
    Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaVenetoclaxPhase 1 / Phase 2Not yet recruitingSecond Affiliated Hospital of Nanchang UniversityNov 9, 2026
    A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsVenetoclaxPhase 3RecruitingBeijing InnoCare Pharma Tech Co., Ltd.Nov 9, 2026
    Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLVenetoclaxNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNov 6, 2026
    This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments, and to Identify and Functionally Validate, at the Single-cell Level, Biomarkers That Can Predict Response to Venetoclax.VenetoclaxNot applicableRecruitingFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOct 14, 2026
    Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLVenetoclaxPhase 2Not yet recruitingRutgers, The State University of New JerseyOct 9, 2026
    Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)VenetoclaxPhase 2Not yet recruitingNational Cancer Institute (NCI)Oct 7, 2026
    Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia PatientsVenetoclax—Not yet recruitingAssiut UniversityOct 1, 2026
    Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLAPG-2575Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaSep 21, 2026
    Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureAPG-2575Phase 2Enrolling by invitationGuangdong Second Provincial General HospitalSep 10, 2026
    Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)APG-2575Phase 2Not yet recruitingPeking University First HospitalJul 21, 2026
    Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsAPG-2575Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo UniversityMay 20, 2026
    Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell LymphomaAPG-2575Phase 2Not yet recruitingHenan Cancer HospitalMar 10, 2026
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseAPG-2575Phase 2RecruitingRuijin HospitalDec 9, 2025
    Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell LymphomaAPG-2575Phase 1 / Phase 2Not yet recruitingFirst Affiliated Hospital of Zhejiang UniversitySep 8, 2025
    Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).APG-2575Phase 3RecruitingAscentage Pharma Group Inc.Oct 15, 2024
    Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaNavitoclaxPhase 2Active, not recruitingPeter MacCallum Cancer Centre, AustraliaMay 18, 2023
    Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsNavitoclaxPhase 1Active, not recruitingJacqueline Garcia, MDJul 13, 2022
    Combination of Olaparib and Navitoclax in Women with HGSC and TNBCNavitoclaxPhase 1Active, not recruitingSunnybrook Health Sciences CentreMay 3, 2022
    Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxNavitoclaxPhase 1Active, not recruitingCity of Hope Medical CenterFeb 3, 2022
    Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxNavitoclaxPhase 1 / Phase 2Active, not recruitingSt. Jude Children's Research HospitalJan 14, 2022
    Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisNavitoclaxPhase 3Active, not recruitingAbbVieJul 13, 2020
    Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisNavitoclaxPhase 1Active, not recruitingAbbVieJul 1, 2020
    A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmNavitoclaxPhase 1Active, not recruitingAbbVieAug 1, 2019

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Neoplasm
    0.60
    Neurodegenerative disease
    0.54
    Prostate carcinoma
    0.53
    Plasma cell myeloma
    0.50
    Type 2 diabetes mellitus
    0.49
    Lymphoid neoplasm
    0.45
    Neoplasm of mature B-cells
    0.45

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4860, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P10415, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.